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OBJECTIVES: To examine the cost-effectiveness of planned
caesarean section versus planned vaginal delivery in breech-
presentation pregnancies at term. METHODS: An incremental
cost-effectiveness analysis was performed using a Markov model
for a hypothetical cohort of 25-year old pregnant women with a
live singleton fetus in a frank or complete breech presentation
at term. Caesarean section was compared with vaginal delivery
from a societal perspective. The model operated over 25 years in
3-year cycles. The model integrated clinical and cost data from
peer-reviewed studies and utilities to estimate cumulative quality-
adjusted life years (QALYs) and costs for both the mother and
infant. Effects and costs were discounted at 4%. Probabilistic
sensitivity analyses were performed to determine key parameter
uncertainty. RESULTS: If only maternal morbidity was taken
into account, caesarean section was more costly and less effective
(incremental cost-effectiveness ratio (ICER) -€54,000 per
QALY), thus vaginal delivery was the dominated strategy. If only
neonatal morbidity and mortality was considered, caesarean
section was less costly and more effective (ICER -€2120 per
QALY). However, if outcomes for both mother and child were
considered, caesarean section was more costly but more effective
(ICER €1275 per QALY). CONCLUSIONS: Caesarean section
resulted to be cost-effective compared to vaginal delivery in
breech presentation at term, if both maternal and neonatal out-
comes were considered. If only maternal condition is considered,
vaginal delivery appeared to be the best strategy.
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OBJECTIVES: To compare the cost-effectiveness of different
therapies for the treatment of dysfunctional uterine bleeding
(DUB) in Spain. METHODS: A decision-analytic model was
built to estimate the clinical and economic consequences of ini-
tiating treatment for DUB with either levonorgestrel intrauterine
system (LNG-IUS), combined oral contraceptives (COC), pro-
gestogens (PROG) or tranexamic acid (TRAX) and switching to
COC (after failure with LNG-IUS or PROG) or to LNG-IUS
(after failure of COC) or to a combination of both (50% to
LNG-IUS and 50% to COC after failure with TRAX), whilst
surgery (hysterectomy and endometrial resection) was assumed
to be used as third line therapy in the base case. Model prob-
abilities were obtained from published systematic reviews and
treatment pathways after initial failure and/or presence of
adverse events (including pregnancy in women requiring contra-
ception) where derived from expert opinion. Local data on health
resources use and costs were used and validated by clinical
experts. Effectiveness was measured as symptom-free months
(SFM) and modelled up to 5 years. The analyses take the per-
spective of the National Health System, so excluding all costs not
supported by the public system (i.e. COC acquisition costs).
RESULTS: Preliminary results show that the higher efﬁcacy of
LNG-IUS translates to a gain of 0.3–3.42 SFM at 5 years. Whilst
LNG-IUS shows a short-term higher cost than the other options,
posterior savings derived from a lower surgery rate, due to a
better control of DUB, yields to cost savings respect to PROG,
COC and TRAX of €158.6, €179.6 and €270.7, respectively.
Furthermore, if surgery is assumed to be the only second line
option after ﬁrst line failures, cost savings with LNG-IUS could
be more than €400 after 5 years. CONCLUSIONS: Preliminary
results of this study indicate that LNG-IUS is a dominant option
with respect to COC, PROG or TRAX, with lower costs and
higher effectiveness than these therapies.
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Inﬂiximab has recently been approved for use in paediatric
patients with severe active Crohn’s disease (CD) and is the only
biologic licensed in this patient population. OBJECTIVES: To
estimate the cost effectiveness of scheduled maintenance treat-
ment with inﬂiximab among children suffering from severe
active CD in Scotland. METHODS: A Markov model was con-
structed to simulate the progression of a hypothetical cohort of
CD children through predeﬁned health states on scheduled
maintenance treatment with inﬂiximab (5 mg/kg) based on
Targan, ACCENT I and REACH trials. The health states used
in the model were remission, therapy (inﬂiximab) responsive
active disease, non-responsive active disease, surgery, post
surgery remission and post surgery complications. Standard
care, comprising immunomodulators and/or corticosteroids
was used as a comparator. The primary outcome was quality
adjusted life years (QALYs) estimated using EQ-5D from a
European CD population. An average patient weight of 40 kg
was used to estimate the dose of inﬂiximab. The costs and
outcomes were discounted at 3.5% over a period of 5 years.
Stochastic sensitivity analyses were performed by varying the
inﬂiximab efﬁcacy estimates, costs and utilities. RESULTS: The
incremental cost effectiveness ratio (ICER) for scheduled main-
tenance treatment with inﬂiximab was £12,483 for severe active
CD children in Scotland. The sensitivity analyses revealed the
analysis time horizon and efﬁcacy estimates to be the most inﬂu-
ential parameters with ICERs ranging from £5,348–£25,950.
CONCLUSIONS: Scheduled maintenance treatment with inﬂix-
imab (5 mg/kg) is a cost effective treatment option for children
suffering from severe active CD under an 8-week scheduled
maintenance programme in Scotland.
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OBJECTIVES: To summarise the existing evidence on the cost
of primary insomnia in persons aged 55 and above in Sweden
and to generate an estimate of its total societal cost based on
national statistics and other public sources. METHODS: We
performed a top-down cost of illness analysis based on the
Living Conditions Survey and national registry data from
the Swedish Social Insurance Board (Forsakringskassan), the
National Board of Health and Welfare (Socialstyrelsen) and the
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national pharmacy (Apoteket AB). Costs were calculated from
a societal perspective by multiplying quantities of resources
used with unit costs (presented in Euros 2007). RESULTS: In
Sweden, about 326,100 patients over 54 years suffer from
acute insomnia (DSM-IV 307.42), a prevalence of about 12%
in this age group. The associated costs exceed €151 million per
year. About 44% are direct costs (outpatient care €40.4 m,
drugs €22.5 m, diagnostic examinations €0.48 m, specialist
visits €0.47 m and inpatient care €0.22 m) and 56% indirect
costs (presenteeism €78.5 m, absenteeism €6.6 m and occupa-
tional and domestic accidents related to daytime dysfunction
caused by poor sleep and current treatment €0.91 m and
€0.57 m, respectively). Other relevant cost items that were not
incorporated in this estimate, due to the high degree of uncer-
tainty, include: cognitive behavioural treatment, productivity
losses due to early retirement, medical costs due to co-
morbidities aggravated by insomnia, side-effects of current
treatment (incl. increased risk of trafﬁc accidents, tolerance,
dependence and withdrawal symptoms), and quality of life
losses. CONCLUSIONS: Our results conﬁrm that insomnia
presents a substantial clinical and economic burden. The
annual cost per patient (€463) is consistent with estimates for
e.g. Germany, France and the US. As a large share of the costs
fall outside the health care system, a societal perspective is
important when evaluating treatments of insomnia.
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OBJECTIVES: To generate national estimates of the inpatient
economic burden of key medical conditions among Asian-
American and Paciﬁc Islander (AAPI) females hospitalized in the
United States in 2005. Conditions analyzed were based upon
research conducted by the US Department of Health and Human
Services, Ofﬁce of Women’s Health, which identiﬁed conditions
of particular concern for this underserved population.
METHODS: Data from the 2005 HCUP Nationwide Inpatient
Sample (NIS) database were analyzed for 438,577 hospital stays
(unweighted = 91,092) for AAPI females. Among these, we iden-
tiﬁed stays in which the primary or second diagnosis, using
relevant ICD-9-CM diagnosis codes, was for tuberculosis (TB),
Hepatitis B (HBV), osteoporosis, cervical cancer (CC), and breast
cancer (BC). Using sampling weights provided with the NIS
dataset, national estimates of mean per-discharge length of stay
(LOS) and total costs, and aggregate (i.e., summed across all
discharges) total days and costs were estimated for each condi-
tion. RESULTS: Among hospitalizations for AAPI women in
2005, we found 485 hospitalizations for TB (with relevant
primary or second diagnosis only), 1237 for HBV, 672 for
osteoporosis, 490 for CC, and 1594 for BC. For each condition,
the mean per-discharge LOS and aggregate total days were 12.3
and 5611; 4.7 and 5804; 3.5 and 2325; 4.7 and 2316; and 2.7
and 4379 days, respectively. Finally, for each condition, the mean
per-discharge and aggregate total costs were $20,563 and
$9,099,718, $10,230 and $11,408,636, $8,284 and $5,269,951,
$10,174 and $4,472,145, and $8,040 and $11,655,081, respec-
tively. CONCLUSIONS: In this study we examined the inpatient
economic burden of illnesses that are of concern for AAPI
women in the US. The total cost incurred for just these 5 condi-
tions (4,478 discharges) was in excess of $40,000,000. Policy
and other decision makers should be aware of the burden of these
conditions as strategies to address these illnesses among this
minority population are developed.
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OBJECTIVES: To assess health care costs associated with a
diagnosis of preeclampsia or hypertension during pregnancy by
describing 5-month antepartum and delivery, and 3-month post-
partum health care costs. METHODS: Pregnancy episodes
(1999–2005) for female claimants ages 15–55 who met continu-
ous enrollment criteria were constructed using a U.S. employer-
based insurance claims database. Episodes were stratiﬁed based
on a diagnosis of preeclampsia (ICD-9 642.4–642.7; N = 2,435),
hypertension during pregnancy (ICD-9 642.0, 642.1, 642.3,
642.9; N = 2,419), or absence of either of these diagnoses
(N = 39,597). Pregnancy-related maternal (5-month antepartum
and delivery, and 3-month postpartum) and neonatal (3-month
postpartum) health care costs were compared using nonparamet-
ric Wilcoxon rank-sum tests, with mean values reported here.
RESULTS: Antepartum and delivery costs were highest for the
preeclampsia group ($13,491), followed by the hypertension
($8,899) and comparison ($8,075) groups (between-group dif-
ferences p < 0.001). Inpatient costs in the preeclampsia group
were 58% ($11,031 vs. $6,961; p < 0.001) and 63% ($11,031
vs. $6,781; p < 0.001) greater than in the hypertension and com-
parison groups, respectively. Maternal postpartum medical costs
in the preeclampsia, hypertension, and comparison groups were
$1623, $1028, and $741, respectively (between-group differ-
ences p < 0.001). Neonatal costs in the preeclampsia group were
much higher than those in the hypertension and comparison
groups ($7035 vs. $2784; p < 0.001 and $7035 vs. $2484;
p < 0.001). More than 60% of all neonatal costs in the preec-
lampsia group were associated with neonatal or pediatric inten-
sive care unit (NICU/PICU) services, compared to less than 40%
in both the hypertension and comparison groups. Total maternal
and neonatal postpartum costs were $8658, $3812, and $3226,
respectively (between-group differences p < 0.001). CONCLU-
SIONS: Pregnancies with a preeclampsia diagnosis are associated
with signiﬁcantly higher maternal antepartum and delivery costs,
and all postpartum costs. Neonatal costs are also signiﬁcantly
higher, largely due to NICU/PICU care of babies born to mothers
with a diagnosis of preeclamspia.
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OBJECTIVES: To evaluate, in a real-life clinical setting, the
utilisation, cost and outcomes of assisted reproduction treatment
(ART) with rFSH and assess whether the economic burden is
consistent with that established by the UK National Institute for
Health and Clinical Excellence (NICE). METHODS: Study
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